by
Lisa Chamoff, Contributing Reporter | October 24, 2022
From the October 2022 issue of HealthCare Business News magazine
Up until recently, HR-pQCT imaging was only available at major research institutions and a few clinical radiology departments. It required a large footprint and qualified users, making it cost-prohibitive for routine clinical evaluation, Singh said. The FDA-cleared InReach HR-pQCT will be offered at a significantly lower price point than other systems, will not require advanced imaging technologists and will have a small footprint, making it more practical for widespread use.
“It takes HR-pQCT out of the research setting and delivers a commercial point-of-care solution to improve bone fragility assessment,” Singh said.
Ad Statistics
Times Displayed: 19605
Times Visited: 366 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
Austin Hospital, located in Melbourne, Australia, has been conducting InReach HR-pQCT research studies with the modality.
CurveBeam plans to launch the InReach HR-pQCT in late 2022.
CurveBeam AI is also exploring building HR-pQCT imaging into its HiRise system, a weight bearing cone beam CT imaging system for the lower extremities, including the hips and pelvis.
“Clinicians would be able to obtain advanced bone health information all from a single scan from the core skeleton, in conjunction with 3D weight-bearing alignment data,” Singh said.
FUJIFILM Healthcare Americas Corporation
In April, FUJIFILM Healthcare Americas Corporation received FDA clearance for its SCENARIA View Focus Edition CT system. The premium scanner is designed for both routine and advanced clinical applications, including interventional CT, extended coverage shuttle scanning for perfusion exams, cardiac CTA and dual-energy examinations.
SCENARIA View Focus Edition can be equipped with Cardio StillShot, which brings a new approach to solving the constant challenge of imaging patients with rapid and irregular heart rates, said Mark Silverman, director of marketing for CT and radiology at FUJIFILM Healthcare Americas Corporation.
The new cardiac motion correction feature acquires two data sets within the target reconstruction stage.
“These data sets are compared against each other to detect and calculate motion,” Silverman said.
With the motion data, Cardio StillShot generates a 4D-motion vector field to deliver images that are free of artifacts, with over six times better temporal resolution than conventional image reconstruction methods, even when imaging patients with irregular and faster heart rates. This enables a higher rate of successful prospectively gated exams and thereby also lowers radiation dose, according to Silverman.
